DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia

Cancer Research

Volumn 66, Issue 10, 2006, Pages 5495-5503

  Yang, Allen S ^a,c   Doshi, Ketan D ^a   Choi, Sang Woon ^b   Mason, Joel B ^b   Mannari, Rajan K ^a   Gharybian, Vazganush ^a   Luna, Rene ^a   Rashid, Asif ^a   Shen, Lanlan ^a   Estecio, Marcos R H ^a   Kantarjian, Hagop M ^a   Garcia Manero, Guillermo ^a   Issa, Jean Pierre J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 METHYLCYTOSINE; PROTEIN P15;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DNA METHYLATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENES, P53; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MUTATION; RNA, UNTRANSLATED;

EID: 33744918070     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2385     Document Type: Article

References (32)

1. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001;134: 573-86.
2. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63.
3. Leone G, Voso MT, Teofili L, Lubbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 2003;109: 89-102.
4. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20: 2429-40.
5. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-95.
6. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 1994; 91:11797-801.
7. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs, and DNA methylation. Cell 1980;20:85-93.
8. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103: 1635-40.
9. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62.
10. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
11. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood 2001;97:2823-9.
12. Garcia-Manero G, Daniel J, Smith TL, et al. DNA Methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 2002;8:2217-24.
13. Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003;22:6489-96.
14. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100: 2957-64.
15. Kantarjian HM, O'Brien S, Cortes, J et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003;98:522-8.
16. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990-7.
17. Cottrell SE, Laird PW. Sensitive detection of DNA methylation. Ann N Y Acad Sci 2003;983:120-30.
18. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 2003; 35:146-50.
19. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004;32:E38.
20. Garcia-Manero G, Daniel J, Mannari R, Chen XQ, Kantarjian H, Issa JP. HoxA5 is hypermethylated at high frequency and density in human leukemias. Proc Annu Meet AACR 2001;42:345.
21. Moulton T, Crenshaw T, Hao Y, et al. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat Genet 1994;7:440-7.
22. Friso S, Choi SW, Girelli D, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A 2002;99: 5606-11.
23. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005;23:3948-56.
24. Jackson-Grusby L, Beard C, Possemato R, et al. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet 2001;27: 31-9.
25. Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 2003;21:277-84.
26. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 2005;65: 7086-90.
27. Samlowski WE, Leachman SA, Wade M, et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005; 23:3897-905.
28. Baylin SB, Fearon ER, Vogelstein B, et al. Hypermethylation of the 5′ region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood 1987;70:412-7.
29. Bender CM, Gonzalgo ML, Gonzales FA, Nguyen CT, Robertson KD, Jones PA. Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol 1999;19:6690-8.
30. Gaudet F, Hodgson JG, Eden A et al. Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489-92.
31. Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on "chromosomal instability and tumors promoted by DNA hypomethylation" and "induction of tumors in nice by genomic hypomethylation." Science 2003;302:1153.
32. Sigalotti L, Altomonte M, Colizzi F, et al. 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 2003;101:4644-6.